source
- Verastem makes its stand as a RevMed competitor in pancreatic cancerVerastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massac…
- Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglu…BioSpace · 8d ago↗ source
- Gilead signs $1.9 billion deal with Vir Biotechnology to license dual-masked T-cell engagers for oncology